Key result
Anti-MCP-1 antibody cuts pleural fluid formation ~88% versus controls in a murine pleurisy model.
Why the study?
The pathobiology of pleural exudate formation remains unclear, although monocyte chemotactic protein-1 has been implicated in fibrinolytic-induced and malignant effusion formation.
Does MCP-1 blockade reduce pleural effusion formation in a carrageenan-induced murine model of pleurisy?
Population
CD1 mice with carrageenan-induced acute pleural inflammation
Comparison
Anti-MCP-1 antibody or CCR2 antagonist vs controls
Design
Preclinical animal study
Follow-up
Up to 16 h post-injection
Authors
Loading...
May inform novel therapies for pleural effusions; leaves open translation from murine models to clinical use.
Does MCP-1 blockade reduce pleural effusion formation in a carrageenan-induced murine model of pleurisy?
Absolute Event Rate: 36% vs 290%
p-value: p=0.02
Blockade of MCP-1 activity significantly reduces inflammatory pleural effusion formation in a murine model, supporting the potential of MCP-1 antagonists for pleural fluid management.
Lansley et al. (2016) studied Acute pleural inflammation and pleural effusion. Anti-MCP-1 antibody vs. Isotype control was evaluated on Pleural fluid formation volume (μL) (p=0.02). Treatment with an anti-MCP-1 antibody significantly reduced pleural fluid formation compared to controls (median 36 μL vs 290 μL, P=0.02) in a murine model of pleurisy.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: